A Conversation w Invivyd's Marc Elia + Dr. Michael Mina: On Monoclonal Antibodies, Treatment v Prevention, and Giving Patients Options

You might remember monoclonal antibodies from the height of the pandemic, when President Trump and later Joe Rogan revealed they'd been treated with them for COVID. On today's episode, we dive into monoclonal antibodies--the science, the hopes, the limitations.

Monoclonal antibodies, the lab-created antibody treatment designed to disrupt a threat, boost your immune system, or even stave off an infection, are already a game-changer for millions of Americans struggling with disease or compromised immune-systems. Today we ask: where is this innovation heading? Can the high costs be reduced? Where does this approach fall in the treatment versus prevention tug of war that emerged during the pandemic? And given the mistrust towards other interventions, are monoclonals heading on a different trajectory?

We're joined by Marc Elia, the chairman of the board for Invivyd, and friend-of-the-pod, Dr. Michael Mina.

Hosts:

Brinda Adhikari

Tom Johnson

Maggie Bartlett

Dr. Mark Abdelmalek

Guests:

Marc Elia, Chairman of the Board of Invivyd, a biopharmaceutical company focused on developing monoclonal antibody platforms

Dr. Michael Mina, epidemiologist, immunologist, and physician. He’s been an associate professor at Harvard Medical School as well as the TH Chan School of Public Health, led America’s test-to-treat program during the pandemic. 

Thanks for listening! If you like us, please leave a review, rate us, and please subscribe! 

Got questions? Comments? We'd love to hear from you! Email us at [email protected]